Rangering i aksjer
#38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Handel Valion Bio, Inc. (VBIO)
Pris VBIO pris med markedsverdi på B
Markedsverdi av Valion Bio, Inc.(VBIO)
Markedsverdi: $681.26K
Per August 2026 har Valion Bio, Inc. en markedsverdi på $681.26K. Dette gjør Valion Bio, Inc. til det 38911th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Valion Bio, Inc. fra 2021 til 2026
VBIO sammenlignet med topp 5 mest populære stocks
| Pris på VBIO |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.470T
|
+802,852,590.36%
|
|
|
|
|
$4.467T
|
+655,704,326.80%
|
|
|
|
|
$4.174T
|
+612,742,230.51%
|
|
|
|
|
$3.700T
|
+543,120,204.32%
|
|
|
|
|
$2.854T
|
+418,978,030.97%
|
